Quantitation of circulating wild-type alpha-1-antitrypsin in heterozygous carriers of the S and Z deficiency alleles

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Donato, L J ^a   Karras, R M ^b   Katzmann, J A ^a   Murray, D L ^a   Snyder, M R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; PEPTIDE; TRYPSIN; BIOLOGICAL MARKER; SERPINA1 PROTEIN, HUMAN;

ALLELE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION COEFFICIENT; HETEROZYGOTE; HUMAN; IMMUNOASSAY; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; PARAMETRIC TEST; S DEFICIENCY ALLELE; TANDEM MASS SPECTROMETRY; WILD TYPE; Z DEFICIENCY ALLELE; BLOOD; FEMALE; GENETICS; MALE; PROCEDURES;

ALLELES; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; BIOMARKERS; CHROMATOGRAPHY, LIQUID; FEMALE; HETEROZYGOTE; HUMANS; MALE; TANDEM MASS SPECTROMETRY;

EID: 84938598476     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0256-9     Document Type: Article

References (25)

1. Lee WL, Downey GP. Leukocyte elastase: physiological functions and role in acute lung injury. Am J Respir Crit Care Med. 2001;164:896-904.
2. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha (1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax. 2004;59:259-64.
3. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365:2225-36.
4. Salahuddin P. Genetic variants of alpha1-antitrypsin. Curr Protein Pept Sci. 2010;11:101-17.
5. Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: molecular pathophysiology. Thorax. 2004;59:529-35.
6. Knaupp AS, Levina V, Robertson AL, Pearce MC, Bottomley SP. Kinetic instability of the serpin Z alpha1-antitrypsin promotes aggregation. J Mol Biol. 2010;396:375-83.
7. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357:605-7.
8. Donato LJ, Jenkins SM, Smith C, Katzmann JA, Snyder MR. Reference and interpretive ranges for alpha (1)-antitrypsin quantitation by phenotype in adult and pediatric populations. Am J Clin Pathol. 2012;138:398-405.
9. Rachelefsky G, Hogarth DK. Issues in the diagnosis of alpha 1-antitrypsin deficiency. J Allergy Clin Immunol. 2008;121:833-8.
10. Snyder MR, Katzmann JA, Butz ML, Wiley C, Yang P, Dawson DB, et al. Diagnosis of alpha-1-antitrypsin deficiency: an algorithm of quantification, genotyping, and phenotyping. Clin Chem. 2006;52:2236-42.
11. Miravitlles M, Herr C, Ferrarotti I, Jardi R, Rodriguez-Frias F, Luisetti M, et al. Laboratory testing of individuals with severe alpha1-antitrypsin deficiency in three European centres. Eur Respir J. 2010;35:960-8.
12. Bornhorst JA, Procter M, Meadows C, Ashwood ER, Mao R. Evaluation of an integrative diagnostic algorithm for the identification of people at risk for alpha1-antitrypsin deficiency. Am J Clin Pathol. 2007;128:482-90.
13. Chen Y, Snyder MR, Zhu Y, Tostrud LJ, Benson LM, Katzmann JA, et al. Simultaneous phenotyping and quantification of alpha-1-antitrypsin by liquid chromatography-tandem mass spectrometry. Clin Chem. 2011;57:1161-8.
14. Bornhorst JA, Greene DN, Ashwood ER, Grenache DG. alpha1-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. Chest. 2013;143:1000-8.
15. Seersholm N. Pi MZ and COPD: will we ever know? Thorax. 2004;59:823-5.
16. Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J. 2005;26:67-76.
17. Ogushi F, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987;80:1366-74.
18. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Pare PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med. 2001;163:469-73.
19. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand. 1978;204:345-51.
20. Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med. 2002;136:270-9.
21. Seersholm N, Wilcke JT, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha (1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med. 2000;161:81-4.
22. Silva GE, Sherrill DL, Guerra S, Barbee RA. A longitudinal study of alpha 1-antitrypsin phenotypes and decline in FEV1 in a community population. Chest. 2003;123:1435-40.
23. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax. 2004;59:843-9.
24. Molloy K, Hersh CP, Morris VB, Carroll TP, O'Connor CA, Lasky-Su JA, et al. Clarification of the risk of chronic obstructive pulmonary disease in alpha 1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014;189:419-27.
25. Sandhaus RA, Turino G, Stocks J, Strange C, Trapnell BC, Silverman EK, et al. alpha1-Antitrypsin augmentation therapy for PI MZ heterozygotes: a cautionary note. Chest. 2008;134:831-4.